Sam Brusco, Associate Editor03.21.23
Etiometry, developer of clinical decision support software for critical care, has earned CE mark and Health Canada authorization for its IVCO2 Index for adults.
The IVCO2 Index helps visualize inadequate carbon dioxide ventilation with other contextual data from the Etiometry platform to inform intervention decisions and get ahead of patient deterioration. It was first FDA-cleared for pediatric use in 2019 and now has CE mark and Health Canada licenses for both pediatric and adult patients.
Etiometry gained FDA clearance for its IDO2 Index in January. The company continues to seek authorizations for all its risk algorithms for both pediatrics and adults in the U.S., Canada, and Europe.
“We are serious in our pursuit to expand authorizations of all four of our current risk indices,” Shane Cooke, CEO of Etiometry told the press. “What drives us forward is knowing how our precision analytics bring situational awareness to strained care teams to help mitigate risk and enhance patient outcomes.”
The software uses mathematical models of human physiology to determine the likelihood that a patient is experiencing inadequate carbon dioxide ventilation (hypercapnia). The IVCO2 Index continuously tracks the probability a patient’s arterial blood gas sample has a partial pressure of CO2 (PaCO2) less than 50 mm Hg. Patient-specific thresholds can also be selected at the bedside.
The Index offers another safety net to spot deterioration in patients with conditions needing tight control of PaCO2 or when V/Q mismatch can hamper PaCO2 management.
The IVCO2 Index helps visualize inadequate carbon dioxide ventilation with other contextual data from the Etiometry platform to inform intervention decisions and get ahead of patient deterioration. It was first FDA-cleared for pediatric use in 2019 and now has CE mark and Health Canada licenses for both pediatric and adult patients.
Etiometry gained FDA clearance for its IDO2 Index in January. The company continues to seek authorizations for all its risk algorithms for both pediatrics and adults in the U.S., Canada, and Europe.
“We are serious in our pursuit to expand authorizations of all four of our current risk indices,” Shane Cooke, CEO of Etiometry told the press. “What drives us forward is knowing how our precision analytics bring situational awareness to strained care teams to help mitigate risk and enhance patient outcomes.”
The software uses mathematical models of human physiology to determine the likelihood that a patient is experiencing inadequate carbon dioxide ventilation (hypercapnia). The IVCO2 Index continuously tracks the probability a patient’s arterial blood gas sample has a partial pressure of CO2 (PaCO2) less than 50 mm Hg. Patient-specific thresholds can also be selected at the bedside.
The Index offers another safety net to spot deterioration in patients with conditions needing tight control of PaCO2 or when V/Q mismatch can hamper PaCO2 management.